A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

NCT06446128 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma, B-cell

Interventions

BIOLOGICAL: CD19/CD20/BCMA CAR T cells

Sponsor

Shanghai Cell Therapy Group Co.,Ltd